Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Bristol-Myers Squibb (NY: BMY )

58.74 -0.04 (-0.07%)
Official Closing Price Updated: 7:00 PM EST, Nov 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
66 67 Next >
Why Is Alzheimer's Player Prothena Stock Trading Higher Today?
Prothena Corporation plc (NASDAQ: PRTA) is reportedly talking to advisors, potentially preparing for a sale. 
Via Benzinga
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) as Adjuvant Treatment for Eligible Patients with Completely Resected Stage IIB or Stage IIC Melanoma1
From Bristol Myers Squibb
Via Business Wire
FDA OKs Pfizer's New Bowel Disease Drug, Analysts Predict Peak Sales Of $3B A Year
The Food and Drug Administration (FDA) approved Pfizer Inc's (NYSE: PFE) Velsipity (etrasimod), an oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor modulator for adults with... 
Via Benzinga
Exposures Product Safety
3 Healthcare Stocks To Make You The Millionaire Next Door: October Edition
These are the healthcare stocks to buy as they represent companies investing in research and development for growth and value creation. 
Via InvestorPlace
Is Bristol Myers Squibb Stock a Buy Now?
Bristol Myers Squibb recently announced an acquisition that should strengthen its oncology portfolio. 
Via The Motley Fool
How Is The Market Feeling About Bristol-Myers Squibb?
Via Benzinga
Bristol-Myers Squibb Unusual Options Activity For October 06
Via Benzinga
When you look at NYSE:BMY, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Don't overlook BRISTOL-MYERS SQUIBB CO (NYSE:BMY)—it's a hidden gem with strong fundamentals and an attractive price tag. 
Via Chartmill
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 4% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high... 
Via Benzinga
Bristol Myers Squibb to Showcase Data Demonstrating Improved Outcomes in Earlier Stages of Cancer, Durable Long-Term Benefits with Opdivo-Based Regimens, and Addressing High Unmet Needs in Multiple Tumor Types at ESMO 2023
From Bristol Myers Squibb
Via Business Wire
Sotyktu (deucravacitinib) Long-Term Data Demonstrate Durable Efficacy and Consistent Safety for up to Three Years in Moderate-to-Severe Plaque Psoriasis
From Bristol Myers Squibb
Via Business Wire
Amgen Stock Surges To 10-Month High, Up 4% On An Unexpected Upgrade
The company has growing pipeline optionality, according to the upgrade report. 
Via Investor's Business Daily
Bristol Myers Squibb Presents New Zeposia (ozanimod) Data on Long-Term Disease Progression and Cognition in Patients with Relapsing Forms of Multiple Sclerosis
From Bristol Myers Squibb
Via Business Wire
7 Innovator Stocks Primed for Exceptional Growth
These featured, inventive companies are not only transforming old sectors but also building bridges toward new ones. 
Via InvestorPlace
Why Shares of Lexicon Pharmaceuticals Are Up Tuesday
Express Scripts will give its clients access to Lexicon's first approved therapy. 
Via The Motley Fool
Why ParaZero Technologies Shares Are Trading Higher By Over 100%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers ParaZero Technologies Ltd. (NASDAQ: PRZO) shares jumped 106% to $2.3901 after the company announced an Australian regulator approved first commercial drone flights in populated areas and near... 
Via Benzinga
Why Shares of Tango Therapeutics Are Dropping Monday
Another company's buyout helped drive up the price last week. This week, investors started out by selling the stock. 
Via The Motley Fool
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Mirati Therapeutics, Inc.® (Nasdaq - MRTX), LiveVox Holdings, Inc. (Nasdaq - LVOX), SP® Plus Corporation (Nasdaq - SP), Summit Materials (NYSE - SUM)
From Brodsky & Smith LLC
Via GlobeNewswire
Mirati Therapeutics Snags $5.8 Billion Takeover Deal, But Shares Fall On Lowball Bid
Bristol Myers Squibb hopes to buy Mirati Therapeutics for up to $5.8 billion. 
Via Investor's Business Daily
Bristol Myers Squibb Strengthens Oncology Portfolio With Mirati Therapeutics' $5B Deal
Bristol Myers Squibb & Co (NYSE: BMY) has agreed to acquire Mirati Therapeutics Inc (NASDAQ: MRTX) for $58.00 per share in cash, for a total  
Via Benzinga
S&P 500, Nasdaq Set For Bleak Start To Week As Middle East Tensions Dampen Risk-On Mood: Earnings, Inflation Data In Focus
Trading in stock futures suggests a lower open on Monday as traders digest the ramification of the conflict in the Middle East. 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Tesla, Mirati Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures traded lower this morning on Monday. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Therapeutics
From Bristol Myers Squibb
Via Business Wire
2 Growth Stocks That Could Rocket Higher Before the End of 2023
Potential approvals of new medicines expected soon could push these stocks through the roof. 
Via The Motley Fool
Thinking Of Buying Alexandria Real Estate Equities? Here Are The Properties And Tenants You'd Add To Your Portfolio
Via Benzinga
5 Low Beta, High-Yield Stocks for Your Low-Risk Income Portfolio
Low-beta stocks offer protection against market downturns and can lead to market-beating performance for investors; high yield helps 
Via MarketBeat
Topics Economy Stocks
Exposures Interest Rates US Equities
Current Analysis: Bristol-Myers Squibb
Over the past year, Bristol’s share price dropped about 20.3% from $71.21 to $56.73 as of Wednesday’s market close. 
Via Talk Markets
Drugmakers Agree To Participate For Medicare Drug Price Negotiation With Biden Administration
All ten manufacturers of the first drugs selected for Medicare price negotiations will be participating, the White House said, even though many of them are suing the administration  
Via Benzinga
Cancer Drug Approval? 3 Biotech Stocks on the Brink of Breakthroughs
CAR T therapies have major advantages over traditional cancer drugs. Here are three of the best cancer drug stocks set to benefit from CAR T. 
Via InvestorPlace
Q4 Stock Predictions: 3 Pharma Stocks Ready to Roar Into 2024
The stars are aligning for these pharmaceutical giants, making their stocks look ready to run higher in next year. 
Via InvestorPlace
< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
66 67 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.